Millora del sistema de comercialització de l'explotació ramadera d'oví de carn Cal Alzina s.c.p. situada al terme municipal de la Roca del Vallès

L’objectiu d’aquest projecte és millorar la rendibilitat de l’explotació ramadera d’oví decarn de Cal Alzina s.c.p a través de la comercialització del seu producte.Es vol complementar l’activitat ramadera de producció de xais que es duu a termeactualment amb el servei de venda del producte al consumidor final, per aconseguireliminar els intermediaris i poder obtenir el màxim benefici. L’explotació de Cal Alzina s.c.p es troba al terme municipal de la Roca del Vallès, està formada per dos socis, els dos propietaris i únics treballadors de l’explotació. Disposa d’un ramat de 922 ovelles de raça Ripollesa amb un sistema semi-extensiu. La venda actual dels xais es fa a través de carnissers que paguen un preu per kg de canal establert pel mercat

Influence of GB virus C on IFN-γ and IL-2 production and CD38 expression in T lymphocytes from chronically HIV-infected and HIV-HCV-co-infected patients

This study was designed to assess the effect of GB virus (GBV)-C on the immune response to human immunodeficiency virus (HIV) in chronically HIV-infected and HIV- hepatitis C virus (HCV)-co-infected patients undergoing antiretroviral therapy. A cohort of 159 HIV-seropositive patients, of whom 52 were HCV-co-infected, was included. Epidemiological data were collected and virological and immunological markers, including the production of interferon gamma (IFN-γ) and interleukin (IL)-2 by CD4, CD8 and Tγδ cells and the expression of the activation marker, CD38, were assessed. A total of 65 patients (40.8%) presented markers of GBV-C infection. The presence of GBV-C did not influence HIV and HCV replication or TCD4 and TCD8 cell counts. Immune responses, defined by IFN-γ and IL-2 production and CD38 expression did not differ among the groups. Our results suggest that neither GBV-C viremia nor the presence of E2 antibodies influence HIV and HCV viral replication or CD4 T cell counts in chronically infected patients. Furthermore, GBV-C did not influence cytokine production or CD38-driven immune activation among these patients. Although our results do not exclude a protective effect of GBV-C in early HIV disease, they demonstrate that this effect may not be present in chronically infected patients, who represent the majority of patients in outpatient clinics.

Lymphocytic choriomeningitis virus-associated meningitis, southern Spain.

Lymphocytic choriomeningitis virus (LCMV) was detected in 2 patients with acute meningitis in southern Spain within a 3-year period. Although the prevalence of LCMV infection was low (2 [1.3%] of 159 meningitis patients), it represents 2.9% of all pathogens detected. LCMV is a noteworthy agent of neurologic illness in immunocompetent persons.

Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.

OBJECTIVE: To estimate the incremental cost-effectiveness of the first-line pharmacotherapies (nicotine gum, patch, spray, inhaler, and bupropion) for smoking cessation across six Western countries-Canada, France, Spain, Switzerland, the United States, and the United Kingdom. DESIGN AND STUDY POPULATION: A Markov-chain cohort model to simulate two cohorts of smokers: (1) a reference cohort given brief cessation counselling by a general practitioner (GP); (2) a treatment cohort given counselling plus pharmacotherapy. Effectiveness expressed as odds ratios for quitting associated with pharmacotherapies. Costs based on the additional physician time required and retail prices of the medications. INTERVENTIONS: Addition of each first-line pharmacotherapy to GP cessation counselling. MAIN OUTCOME MEASURES: Cost per life-year saved associated with pharmacotherapies. RESULTS: The cost per life-year saved for counselling only ranged from US190 dollars in Spain to 773 dollars in the UK for men, and from 288 dollars in Spain to 1168 dollars in the UK for women. The incremental cost per life-year saved for gum ranged from 2230 dollars for men in Spain to 7643 dollars for women in the US; for patch from 1758 dollars for men in Spain to 5131 dollars for women in the UK; for spray from 1935 dollars for men in Spain to 7969 dollars for women in the US; for inhaler from 3480 dollars for men in Switzerland to 8700 dollars for women in France; and for bupropion from 792 dollars for men in Canada to 2922 dollars for women in the US. In sensitivity analysis, changes in discount rate, treatment effectiveness, and natural quit rate had the strongest influences on cost-effectiveness. CONCLUSIONS: The cost-effectiveness of the pharmacotherapies varied significantly across the six study countries, however, in each case, the results would be considered favourable as compared to other common preventive pharmacotherapies.

The β-sliding clamp directs the localization of HdaA to the replisome in Caulobacter crescentus.

The initiation of chromosome replication is tightly regulated in bacteria to ensure that it takes place only once per cell cycle. In many proteobacteria, this process requires the ATP-bound form of the DnaA protein. The regulatory inactivation of DnaA (RIDA) facilitates the conversion of DnaA-ATP into replication-inactive DnaA-ADP, thereby preventing overinitiation. Homologues of the HdaA protein, together with the β-clamp of the DNA polymerase (DnaN), are required for this process. Here, we used fluorescence resonance energy transfer experiments to demonstrate that HdaA interacts with DnaN in live Caulobacter crescentus cells. We show that a QFKLPL motif in the N-terminal region of HdaA is required for this interaction and that this motif is also needed to recruit HdaA to the subcellular location occupied by the replisome during DNA replication. An HdaA mutant protein that cannot colocalize or interact with DnaN can also not support the essential function of HdaA. These results suggest that the recruitment of HdaA to the replisome is needed during RIDA in C. crescentus, probably as a means to sense whether chromosome replication has initiated before DnaA becomes inactivated. In addition, we show that a conserved R145 residue located in the AAA+ domain of HdaA is also needed for the function of HdaA, although it does not affect the interaction of HdaA with DnaN in vivo. The AAA+ domain of HdaA may therefore be required during RIDA after the initial recruitment of HdaA to the replisome by DnaN.

Influencia de los esquemas cognitivos implícitos y explícitos en la manifestación de experiencias pseudo-psicóticas positivas

El presente estudio evalúa la influencia de los esquemas implícitos y explícitos, tanto acerca de uno mismo como de los demás, sobre la experimentación de experiencias pseudo-psicóticas positivas; tomando como marco de referencia dos destacados modelos explicativos: el modelo atribucional de auto-representación y el modelo de la anticipación cognitiva de la amenaza. Los análisis se realizaron sobre una muestra de 185 estudiantes de psicología de la UAB. Los resultados obtenidos apoyaron la influencia de los esquemas explícitos positivos del yo y los negativos de los otros sobre las experiencias pseudo-psicóticas positivas; aportando así un apoyo parcial para ambos modelos.

Proceso de gestión de denuncias

El Manual de Procesos en Protección de la Salud estableció cuales eran los procesos operativos o claves que debían ser diseñados e implementados dentro del marco del II Plan de Calidad del Sistema Sanitario Publico de Andalucía. El fin último de elaborar un proceso operativo relacionado con las denuncias, es dar respuesta a la demanda habitual de la ciudadanía de poner en conocimiento de la Administración Pública los posibles incumplimientos o posibles riesgos en el ámbito de la protección de la salud.

Celebrada la II Jornada del Observatorio de Medio Ambiente y Salud de Andalucía

Boletín semanal para profesionales sanitarios de la Secretaría General de Salud Pública y Participación Social de la Consejería de Salud

Estudio ansiedad-depresión del Donante Trasplante Renal vivio asociado con compartir o no la habitación con el receptor

En las últimas décadas, el Trasplante Renal demuestra ser el mejor tratamiento sustitutivo de la Insuficiencia Renal Crónica, siendo el Trasplante Renal de donante vivo la mejor elección en cuanto calidad de vida, supervivencia del injerto, menores complicaciones y menor coste-beneficio para el trasplantado. En la Fundación Puigvert de Barcelona, la pareja, donante-receptor, de trasplante renal de donación de vivo permanecen juntos durante el procedimiento, mientras que en otros Centros Hospitalarios Nacionales la estancia es separada durante todo el procedimiento o en el post-operatorio. El presente trabajo es un ensayo clínico cuyo objetivo es comprobar si la pareja donante receptor de trasplante renal vivo que comparte estancia hospitalaria en el proceso de la donación modifica su estado afectivo, el físico y la estancia hospitalaria frente aquellos que no la comparten. La población diana son parejas de donante-receptor de nuestro Centro dónde se lleva a cabo el proceso del trasplante renal. La estimación de la muestra necesaria es de 18 parejas en cada grupo, se fija un nivel de significación del 5% y el nivel de pérdidas. El Análisis estadístico se realizará mediante el test 2 de Pearson para las variables independientes cualitativas y el test t-student o Test Shapiro-Wilk. Procedimiento: Grupo A, pareja que ingresa en la misma habitación y Grupo B, pareja que ingresa en habitaciones diferentes. En primer lugar, mediante un estudio exploratorio se conoce la sintomatología de ansiedad-depresión que presenta la pareja donante-receptor previo al ingreso hospitalario y en la segunda parte, se establece un grupo control (estancia junta del donante y receptor) y un grupo experimental (estancia separada del donante y receptor). Se analizan tres momentos diferentes: el antes del ingreso hospitalario, el previo a la intervención quirúrgica y el día del alta hospitalaria.

Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.

BACKGROUND: Metabolic complications, including cardiovascular events and diabetes mellitus (DM), are a major long-term concern in human immunodeficiency virus (HIV)-infected individuals. Recent genome-wide association studies have reliably associated multiple single nucleotide polymorphisms (SNPs) to DM in the general population. METHODS: We evaluated the contribution of 22 SNPs identified in genome-wide association studies and of longitudinally measured clinical factors to DM. We genotyped all 94 white participants in the Swiss HIV Cohort Study who developed DM from 1 January 1999 through 31 August 2009 and 550 participants without DM. Analyses were based on 6054 person-years of follow-up and 13,922 measurements of plasma glucose. RESULTS: The contribution to DM risk explained by SNPs (14% of DM variability) was larger than the contribution to DM risk explained by current or cumulative exposure to different antiretroviral therapy combinations (3% of DM variability). Participants with the most unfavorable genetic score (representing 12% and 19% of the study population, respectively, when applying 2 different genetic scores) had incidence rate ratios for DM of 3.80 (95% confidence interval [CI], 2.05-7.06) and 2.74 (95% CI, 1.53-4.88), respectively, compared with participants with a favorable genetic score. However, addition of genetic data to clinical risk factors that included body mass index only slightly improved DM prediction. CONCLUSIONS: In white HIV-infected persons treated with antiretroviral therapy, the DM effect of genetic variants was larger than the potential toxic effects of antiretroviral therapy. SNPs contributed significantly to DM risk, but their addition to a clinical model improved DM prediction only slightly, similar to studies in the general population.